First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2 in HER2-negative, Advanced Gastric or GEJ Adenocarcinoma By Ogkologos - March 24, 2026 260 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ILUSTRO study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Metastatic Breast Cancer: New ESMO Guideline With Evidence-Based Recommendations [ESMO Press... October 19, 2021 Trial Tests Abemaciclib As New Option for Early-Stage Breast Cancer January 6, 2021 Doing More—Together—to End Cancer as We Know It February 9, 2023 Pembrolizumab Plus Chemoradiotherapy Significantly Improves OS in Patients with Locally Advanced... October 11, 2024 Load more HOT NEWS Appendix Cancers Are Genetically Distinct from Other Gastrointestinal Cancers, Study Shows Prostate Cancer Prevention and Finasteride: A Conversation with NCI’s Dr. Howard... Survey results reveal attitudes towards cancer screening during the pandemic FDA Sends Out Warning To Dollar Tree For Selling “Potentially Unsafe...
